Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001952699 | SCV002210124 | uncertain significance | Marfan syndrome; Familial thoracic aortic aneurysm and aortic dissection | 2021-06-16 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid with glutamic acid at codon 648 of the FBN1 protein (p.Asp648Glu). The aspartic acid residue is highly conserved and there is a small physicochemical difference between aspartic acid and glutamic acid. This variant is not present in population databases (ExAC no frequency). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with FBN1-related conditions. |
| Greenwood Genetic Center Diagnostic Laboratories, |
RCV003314026 | SCV004013436 | uncertain significance | not provided | 2023-04-27 | criteria provided, single submitter | clinical testing | PM2 |
| All of Us Research Program, |
RCV004804317 | SCV005424895 | uncertain significance | Marfan syndrome | 2024-03-05 | criteria provided, single submitter | clinical testing |